Last reviewed · How we verify
metformin, glimepiride, insulin
At a glance
| Generic name | metformin, glimepiride, insulin |
|---|---|
| Sponsor | Sorlandet Hospital HF |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Musculoskeletal
- Infections
- Nervous system
- General Disorders
- Gastrointestinal Disorders
- Injury
- Respiratory
- Skin
- Eye Disorders
- Psychiatric
- Investigations
- Renal
Key clinical trials
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (PHASE4)
- BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
- Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy
- The Effect of Glimepiride Compared With Sitagliptin as an add-on Therapy to Metformin in Severe Insulin Deficiency Diabetes (PHASE4)
- Risk Reduction in Coronary Heart Disease (NA)
- Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan (PHASE4)
- A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- metformin, glimepiride, insulin CI brief — competitive landscape report
- metformin, glimepiride, insulin updates RSS · CI watch RSS
- Sorlandet Hospital HF portfolio CI